Anbio Biotechnology (NNNN) Accumulated Expenses (2023 - 2025)

Anbio Biotechnology (NNNN) has reported Accumulated Expenses for 3 consecutive years, with $87836.0 the latest figure, recorded in Q4 2025.

• In Q4 2025, Accumulated Expenses fell 16.33% year-over-year to $87836.0; the TTM figure through Dec 2025 stood at $87836.0 (down 16.33% YoY), while the FY2025 annual figure was $87836.0, down 16.33% from the prior year.
• Accumulated Expenses slipped to $87836.0 in Q4 2025 per NNNN's latest filing, from $104979.0 in the prior quarter.
• Across five years, Accumulated Expenses topped out at $130967.0 in Q4 2023 and bottomed at $87836.0 in Q4 2025.
• Historically, Accumulated Expenses has averaged $107927.3 across 3 years, with a median of $104979.0 in 2024.
• Annual changes were most pronounced in 2024 — Accumulated Expenses dropped 19.84% — and 2025, when it retreated 16.33%.
• Anbio Biotechnology's Accumulated Expenses stood at $130967.0 in 2023, then retreated by 19.84% to $104979.0 in 2024, then fell by 16.33% to $87836.0 in 2025.
• Business Quant data shows NNNN's Accumulated Expenses at $87836.0 in Q4 2025, $104979.0 in Q4 2024, and $130967.0 in Q4 2023.